Geode Capital Management LLC Decreases Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Geode Capital Management LLC lowered its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 3.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,292,100 shares of the company’s stock after selling 42,359 shares during the period. Geode Capital Management LLC’s holdings in Zentalis Pharmaceuticals were worth $4,756,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ZNTL. GSA Capital Partners LLP grew its position in shares of Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after purchasing an additional 353,384 shares in the last quarter. Decheng Capital LLC raised its position in Zentalis Pharmaceuticals by 46.2% in the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after purchasing an additional 970,859 shares during the period. XTX Topco Ltd lifted its stake in Zentalis Pharmaceuticals by 1,581.9% in the second quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock worth $730,000 after purchasing an additional 167,854 shares during the last quarter. Verition Fund Management LLC grew its position in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after acquiring an additional 951,500 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Zentalis Pharmaceuticals by 152.6% during the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after buying an additional 399,745 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ZNTL. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Guggenheim lowered their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $3.24 on Monday. The stock has a market cap of $230.90 million, a P/E ratio of -1.30 and a beta of 1.84. The firm’s 50 day moving average price is $3.33 and its 200-day moving average price is $3.50. Zentalis Pharmaceuticals, Inc. has a 1 year low of $2.66 and a 1 year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. As a group, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.